Herpes simplex virus thymidine kinase gene transduction enhances tumor growth rate and cyclooxygenase-2 expression in murine colon cancer cells

Cancer Gene Therapy

Volumn 11, Issue 12, 2004, Pages 830-840

  Konson, Alexander ^a   Ben Kasus, Tsipi ^a   Mahajna, Jamal A ^b   Danon, Abraham ^a   Rimon, Gilad ^a   Agbaria, Riad ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

Author keywords

Cyclooxygenase; Ganciclovir resistant; HSV thymidine kinase; Tumor growth

Indexed keywords

CYCLOOXYGENASE 2; GANCICLOVIR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NEOMYCIN; NIMESULIDE; PROSTAGLANDIN E2; RETROVIRUS VECTOR; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; CANCER CELL; CANCER TRANSPLANTATION; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; GENE INSERTION; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSDUCTION; GROWTH RATE; HERPES SIMPLEX VIRUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; TUMOR GROWTH;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; ENZYME ACTIVATION; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; MICE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS E; SIMPLEXVIRUS; SULFONAMIDES; THYMIDINE KINASE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ANIMALIA; INSERTION SEQUENCES; MURINAE; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 10444280991     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700768     Document Type: Article

References (55)

1. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 1990;82:297-300.
2. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1:279-287.
3. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997;12:1354-1361.
4. Zwacka RM, Dunlop MG. Gene therapy for colon cancer. Hematol Oncol Clin North Am. 1998;12:595-615.
5. Matsubara H, Kawamura K, Sugaya M, et al. Differential efficacy of suicide gene therapy by herpes simplex virus-thymidine kinase gene reflects the status of p53 gene in human esophageal cancer cells. Anticancer Res. 1999;19:4157-4160.
6. Cho HS, Park YN, Lyu CJ, et al. Effects of retroviral-mediated herpes simplex virus thymidine kinase gene transfer to murine neuroblastoma cell lines in vitro and in vivo. Acta Oncol. 1999;38:1093-1097.
7. Wildner O. In situ use of suicide genes for therapy of brain tumors. Ann Med. 1999;31:421-429.
8. Moriuchi S, Krisky DM, Marconi PC, et al. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Therapy. 2000;7:1483-1490.
9. Zhang L, Wikenheiser KA, Whitsett JA. Limitations of retrovirus-mediated HSV-tk gene transfer to pulmonary adenocarcinoma cells in vitro and in vivo. Hum Gene Ther. 1997;8:563-574.
10. Garin MI, Garrett E, Tiberghien P, et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood. 2001;97:122-129.
11. Needleman P, Turk J, Jakschik BA, et al. Arachidonic acid metabolism. Annu Rev Biochem. 1986;55:69-102.
12. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993;330:156-160.
13. Williams CS, DuBois RN. Prostaglandin eudoperoxide synthase: why two isoforms? Am J Physiol. 1996;270: G393-G400.
14. Birkle DL, Sanitato JJ, Kaufman HE, Bazan NG. Arachidonic acid metabolism to eicosanoids in herpes virus-infected rabbit cornea. Invest Ophthalmol Vis Sci. 1986;27:1443-1446.
15. Heitman CR, Waite M, Kucera LS. Studies of phospholipase and cyclooxygenase activities in herpes simplex virus type 2-transformed rat cells. Carcinogenesis. 1989;10:2059-2065.
16. Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA. 2001;98:6905-6910.
17. Pereira CF, Boven LA, Middel J, et al. Induction of cyclooxygenase-2 expression during HIV-1-infected monocyte-derived macrophage and human brain microvascular endothelial cell interactions. J Leukoc Biol. 2000;68:423-428.
18. Bagetta G, Corasaniti MT, Paoletti AM, et al. HIV-1 gp120-induced apoptosis in the rat neocortex involves enhanced expression of cyclo-oxygenase type 2 (COX-2). Biochem Biophys Res Commun. 1998;244:819-824.
19. Mori N, Inoue H, Yoshida T, et al. Constitutive expression of the cyclooxygenase-2 gene in T-cell lines infected with human T-cell leukemia virus type I. Int J Cancer. 2001;94:813-819.
20. Hirschowitz E, Hidalgo G, Doherty D. Induction of cyclooxygenase-2 in non-small cell lung cancer cells by infection with DeltaE1, DeltaE3 recombinant adenovirus vectors. Gene Therapy. 2002;9:81-84.
21. Wachsman M, Aurelian L, Burnett JW. The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections. Br J Dermatol. 1990;123:375-380.
22. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol. 1992;263:F181-F191.
23. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001;2:544-551.
24. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003;24:96-102.
25. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids. 1996;54:83-94.
26. Tsuji S, Tsujii M, Kawano S, Hori M. Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. J Exp Clin Cancer Res. 2001;20:117-129.
27. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 1998;58:4823-4826.
28. Ohno R, Yoshinaga K, Fujita T, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer. 2001;91:1876-1881.
29. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (II). J Natl Cancer Inst. 1998;21:1609-1620.
30. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst. 1999;91:1501-1504.
31. Chen Q, Shinohara N, Abe T, Watanabe T, Nonomura K, Koyanagi T. Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer. 2004;108:825-832.
32. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997;94:3336-3340.
33. Leung WK, To KF, Go MY, et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol. 2003;23:1317-1322.
34. Fujita H, Koshida K, Keller ET, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate. 2002;53:232-240.
35. Degr'eve B, De Clercq E, Balzarini J. Selection of HSV-1 TK gene-transfected murine mammary carcinoma cells resistant to (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and ganciclovir (GCV). Gene Therapy. 2000;7:1543-1552.
36. Chou TC, Haball M. CalcuSyn for Windows, Multiple-Drug Dose-effect Analyzer and Manual, Cambridge, UK: Biosoft; (1996).
37. Agbaria R, Candotti F, Kelley JA, et al. Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells. Biochem Biophys Res Commun. 2001;289:525-530.
38. Noy R, Ben-Zvi Z, Elezra M, et al. Pharmacokinetics and organ distribution of N-methanocarbathymidine, a novel thymidine analog, in mice bearing tumors transduced with the herpes simplex thymidine kinase gene. Cancer Chemother Pharmacol. 2002;50:360-366.
39. Danon A, Leibson V, Assouline G. Effects of aspirin, indomethacin, flufenamic acid and paracetamol on prostaglandin output from rat stomach and renal papilla in vitro and ex vivo. J Pharm Pharmacol. 1983;35:576-579.
40. D'Acquisto F, Iuvone T, Rombola L, et al. Involvement of NF-κB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett. 1997;418:175-178.
41. Lowry OH, Roseborough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem. 1951;193:265-275.
42. Bishop-Bailey D, Calatayud S, Warner TD, et al. Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol. 2002;21:93-101.
43. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58:409-412.
44. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 1997;99:2254-2259.
45. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000;60:2101-2103.
46. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 2002;62:6706-6711.
47. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 2000;105:1589-1594.
48. Pentland AP, Schoggins JW, Scott GA, et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis. 1999;20:1939-1944.
49. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000;60:293-297.
50. Okajima E, Denda A, Ozono S, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 1998;58:3028-3023.
51. Denda A, Kitayama W, Murata A, et al. Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a chorine-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. Carcinogenesis. 2002;23:245-256.
52. Smith ML, Hawcroft G, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer. 2000;36:664-674.
53. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057-2072.
54. DuBois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
55. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclooxygenase-2 gene. Biochem J. 1994;302:723-727.